Research Study

A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects With Moderate to Severe Atopic Dermatitis
Principal Investigator 
Vincent C. Ho

Overview

Body Locations and Systems 
Dermatitis
ClinicalTrials.gov# 
NCT03607422
Status 
Closed for Recruitment
Study Start/End 
Jun 25, 2019 to Dec 31, 2022
Locations 
Vancouver General Hospital
Name/Title 
Grace Mak, Study Coordinator
Phone 
604-875-5296
Email Address 
grace.mak@ubc.ca
Purpose of Study 

 

The objective of this study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult participants with moderate to severe AD who are candidates for systemic therapy.

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.